Abstract
Osteosarcoma is the most common primary bone tumor in children, and only 1 article in the literature describes a case of osteosarcoma in a patient with Down syndrome. Although osteosarcoma is generally treated with chemotherapy regimens that include high-dose methotrexate, patients with Down syndrome have heightened sensitivity to the toxicities of methotrexate. The patient from the aforementioned case study died from sepsis soon after treatment with high-dose methotrexate. This case report describes the successful treatment of osteosarcoma in a pediatric patient with Down syndrome without methotrexate.
Original language | English (US) |
---|---|
Pages (from-to) | 71-73 |
Number of pages | 3 |
Journal | Journal of Pediatric Hematology/Oncology |
Volume | 41 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2019 |
Keywords
- methotrexate
- osteosarcoma
- trisomy 21
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology